The pharmaceutical company’s market share in Romania also declined, to 5.4% in 2012 from 6% in 2011.
“According to Cegedim, we’ve had a decline. Competition on the generics market has intensified and we haven’t had replacement options in Romania because the reimbursed medicines list was closed. We are now hoping the reimbursed medicines list will be updated and we’ll launch 12 new products, most of which are cancer medicines,” said Prigent.
In the first quarter of 2013, GSK Romania sales decreased 16.5%, to RON151.9 million from RON182.1 million in the same period of 2012.
GSK’s portfolio in Romania includes vaccines and respiratory, urology, HIV, hematology, oncology, and dermatology medicines.
The company announced earlier this week it is looking to sell its production unit in Brasov, central Romania, or it will shut it down in 2015.
GSK also owns drug distributor Europharm Distributie in Romania.
GSK is the world’s sixth largest drugmaker, with sales of $32.7 billion last year, according to IMS Health.